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Abstract
Pancreatic b-cell failure on a background of insulin resistance results in the inability to compensate for
fasting hyperglycaemia and eventually produces type 2 diabetes mellitus. We describe an interesting
case of a patient who presented acutely with unprovoked severe hyperglycaemic hyperosmolar state
and was subsequently diagnosed with type 2 diabetes mellitus on a background of only impaired first
phase insulin secretion 4 months prior. Glucagon stimulation test detected significant b-cell failure
necessitating long term exogenous insulin therapy which is highly unusual by virtue of the rapid
apparent deterioration.
Introduction
Type 2 Diabetes Mellitus (T2DM) is undoubtedly the
scourge of the developed world and a source of consider-
able socioeconomic burden [1]. It accounts for 90-95% of
diabetes cases worldwide [2]. Although the exact aetiology
of T2DM remains unknown, it involves a combination of
insulin resistance and some degree of pre-existing b-cell
secretory dysfunction conferring a state of relative rather
than absolute insulin deficiency which progressively
deteriorates with time irrespective of treatment [2-5].
Individuals at risk of developing overt T2DM, including
the pre-diabetic states of impaired glucose tolerance (IGT)
and impaired fasting glycaemia (IFG) already exhibit b-cell
dysfunction and the weight of evidence suggests that this
occurred long before the onset of pre-diabetes, when
normal fasting glucose was still present [5,6].
Pancreatic b-cell compensation initially keeps glycaemia
near normal despite underlying insulin resistance by
increasing insulin secretion during the normoglycaemic
and pre-diabetes stages [3-5]. The failure of b-cells to
compensate at some point leads to development of overt
T2DM [5,6]. This b-cell failure develops in a progressive
fashion and continues after diagnosis, frequently resulting
in secondary failure and exogenous insulin requirement
[5,6]. It has not been reported <6 months from detection
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case where the duration between onset of initial abnorm-
ality in glucose homeostasis and apparent b-cell failure
necessitating long term exogenous insulin therapy is
unusually rapid.
Case presentation
A 73-year-old Caucasian male presented to the Emergency
Department (ED) in June 2008 with a history of collapse
without loss of consciousness while mobilizing to the
toilet in the early hours of the morning. This occurred on
the background of a 6 day history of general unwellness.
He was conscious and orientated on arrival but was
slightly drowsy. Other than clinical features of dehydra-
tion and mild central abdominal adiposity with a waist:
hip ratio of 1.04, there were no other significant clinical
signs. His random plasma glucose (RPG) on arrival was
59.1 mmol/L. His height was 1.76 meters (m) and weight
was 90 kilograms (kg) making the body mass index (BMI)
29.0 kg/m
2. The patient was previously fit and well
without any known co-morbidities. He was on no regular
medication. There was no family history of diabetes or
other significant conditions. He was a non-smoker and
consumed no alcohol. He works as a farm equipment
evaluator. There was no history of specific weight loss over
the preceding months. His general practitioner (GP) had
performed a fasting plasma glucose test on him in
February 2008 which showed a value of 6.4 mmol/L.
This was repeated within 2 weeks and the repeated value
was 6.1 mmol/L. Glycosylated haemoglobin (HbA1c) was
also done and was 6.3%. Subsequent 75 gram (g) oral
glucose tolerance test (OGTT) produced a value of
15.3 mmol/L, 14.1 mmol/L and 7.6 mmol/L 30 minutes,
1-hour and 2-hours post glucose load respectively. He was
managed with dietary modification and exercise.
Hissodium(Na)was150mmol/L,potassium(K)4.6mmol/
L, urea 26.1 mmol/L and creatinine (Cr) 237 micromol/L.
Calculated osmolality was 394.4 mOsm/kg. Arterial blood
gas sampling (ABG) showed a pH of 7.36, pCO2 4.9 kPa,
pO2 11.0 kPa, bicarbonate 20 mmol/L and BE -1 mmol/L.
Lactate was mildly elevated at 1.4 mmol/L. b-hydroxybuty-
rate (b-OHB) was slightly elevated at 3.67 mmol/L. Repeat
HBA1c was 8.1%. Besides a small amount of ketones and
glycosuria, urine testing revealed nil else of concern. Full
septic screen was done; white cell count (WCC) and
differential showed mildly raised WCC at 12.5 × 109 and
neutrophils at 10.9 × 109 with the rest of differential count
being normal, CRP was 4, urine microscopy, culture and
sensitivity was normal and chest radiograph was normal.
Thyroid function was normal. Lipid profile was also normal.
The patient was diagnosed with T2DM based on his
presentation, age and absence of anti-Glutamic Acid
Decarboxylase 65 (Anti-GAD 65), Insulinoma Antigen-2
(IA-2) and Islet Cell (ICA) antibodies. His acute presenta-
tion was consistent with hyperglycaemic hyperosmolar
state (HHS) and acute renal failure secondary to dehydra-
tion. He was treated with intravenous insulin and
intensively rehydrated with close attention to electrolyte
balance. He improved considerably and renal function
normalized. He was started on Metformin 500 mg
twice daily (BID) increasing to 1 g BD and Penmix
30 subcutaneous insulin at a dose of 12 units BD
increasing to 30 units BD. 5 days after the acute event, a
1 mg intravenous (IV) glucagon stimulation test was done
at 9.00 am with blood samples for glucose and C-peptide
taken at baseline, 5, 10 and 15 minutes.
Patient had been fasted for 15 hours overnight and
medications were withheld until after the test. The glucose
values were 6.3 mmol/L, 15.1 mmol/L, 16.3 mmol/L and
16.6 mmol/L at baseline, 5, 10 and 15 minutes respec-
tively. Corresponding C-peptide values were 0.21 nmol/L,
0.42 nmol/L, 0.47 nmol/L and 0.51 nmol/L respectively.
He was finally discharged after 7 days of hospital care with
clinic follow up in 2 months. His average capillary blood
glucose (CBG) was 6.7 mmol/L and range 6.5-7.7 mmol/L
on discharge.
Discussion
The OGTT results prior to admission provided surrogate
informationonfirstphaseinsulinsecretionwiththerelative
inability to clear glucose 30 minutes post load being
suggestiveoffirstphaseinsulinsecretorydefectcharacteristic
of IGM [8]. At that stage, the patient could be classified
as having mixed IFG/IGT but did not meet criteria for
diagnosis of T2DM [2]. Subsequent admission with overt,
apparently unprovoked HHS and full blown T2DM requir-
ing insulintoachieveglycaemic control within4 monthsof
identification of IGM in a previously treatment naïve
individualishighlyunusual[6].Inaddition,theIVglucagon
stimulation test demonstrated the inability of b-cells to
respond to hyperglycaemia which not only confirmed
established T2DM, but also significant b-cell failure [3-5].
Homeostasis model assessment-insulin resistance
(HOMA-IR), reciprocal HOMA-IR and quantitative insulin
sensitivitycheckindex(QUICKI)werenotdonetoconfirm
insulin resistance or state of insulin sensitivity since these
calculations require intact b-cell function (fasting insulin
and glucose levels) [9]. Other complex tests and calcula-
tions for insulin sensitivity/insulin resistance or for
assessment of b-cell function were not performed as they
weredeemedtobemoreappropriateincontrolledresearch
settings and beyond the ethical scope of a case report.
Pancreatic b-cell function is reported to be about
50%-60% of normal at the time of diagnosis of T2DM
regardless of severity of insulin resistance [3,4,6]. The
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failure are a matter of intense interest due to the obvious
potential for therapy. The b-cell dysfunction and eventual
failure involves b-cell secretory defects (manifesting as loss
of first and then second phases of insulin secretion,
reduced diurnal oscillations and impaired rapid pulsatile
secretion) and reduction of b-cell mass [3-6]. Research has
revealed several potential causes including glucotoxicity,
lipotoxicity, proinflammatory cytokines secreted by adi-
pose tissue and immune system and islet amyloid
deposition [3-6]. Recent research even provided a possible
cellular level common pathway by which b-cell failure can
occur, involving the unfolded protein response (UPR)
signalling pathways in the endoplasmic reticulum (ER)
[10]. Regardless, it is fair to say that we do not yet know
the exact cause(s) of b-cell dysfunction and failure. With
regards to thepossible factor(s) wedo knowabout, there is
no conclusive data about the actual duration needed to
cause significant b-cell dysfunction and hence onset of
T2DM, although the process is thought to occur over years
rather than months [3-6]. In this patient, the rapid
apparent deterioration of b-cell function cannot
be adequately explained by lipotoxicity or glucotoxicity
since there was no hyperlipidaemia or significantly raised
plasma glucose previously. The possibility that acute
glucotoxicity during the HHS affected the IV glucagon
stimulation test result is unlikely since the test was done
5 days later, when the patient already had good glycaemic
control. Even if the above mentioned causes existed in this
patient, the rapid progression profile makes it unlikely that
they were of any major importance.
Conclusion
Although progression from IGM to T2DM is an expected
course in the spectrum of the disease, rapid b-cell failure
and development of insulin requiring T2DM within a few
months of IGM is unusual. Therefore, this case suggests the
pervasive likelihood of other, yet undetected factor(s),
which may cause uncharacteristically rapid b-cell failure
and rapid progression from normal glycaemia to IGM and
overt insulin requiring T2DM.
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